These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6814594)

  • 41. Medical adrenalectomy with aminoglutethimide-cortisol in the treatment of metastatic breast carcinoma.
    Paridaens R; Van Haelen C; Heuson JC
    Eur J Cancer (1965); 1980; Suppl 1():103-6. PubMed ID: 7318860
    [No Abstract]   [Full Text] [Related]  

  • 42. Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer.
    Kaye SB; Woods RL; Fox RM; Coates AS; Tattersall MH
    Cancer Res; 1982 Aug; 42(8 Suppl):3445s-3447s. PubMed ID: 6177404
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma.
    Smith IE; Harris AL; Morgan M; Gazet JC; McKinna JA
    Cancer Res; 1982 Aug; 42(8 Suppl):3430s-3433s. PubMed ID: 7044525
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Megestrol acetate in advanced breast carcinoma after failure to tamoxifen and/or aminoglutethimide.
    Brufman G; Isacson R; Haim N; Gez E; Sulkes A
    Oncology; 1994; 51(3):258-61. PubMed ID: 8196908
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial.
    Smith IE; Harris AL; Morgan M; Ford HT; Gazet JC; Harmer CL; White H; Parsons CA; Villardo A; Walsh G; McKinna JA
    Br Med J (Clin Res Ed); 1981 Nov; 283(6304):1432-4. PubMed ID: 6797571
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Hormonal therapy of breast cancer].
    Espié M
    Bull Cancer; 1994; 81(10 Suppl):5-7. PubMed ID: 7718950
    [No Abstract]   [Full Text] [Related]  

  • 47. [The use of aminoglutethimide in the treatment of metastatic breast cancer].
    Bellora MG; Ciancio A; Ferrero A; Bergamino T; Zola P; Sismondi P
    Minerva Ginecol; 1991 Dec; 43(12):589-93. PubMed ID: 1819778
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Current status of hormonotherapy of metastatic cancer of the breast].
    Namer M
    Bull Cancer; 1989; 76(1):65-73. PubMed ID: 2713517
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical experiences with tamoxifen for estrogen receptor blocking therapy in metastatic breast cancer.
    Henningsen B
    Prog Clin Biol Res; 1977; 12():479-82. PubMed ID: 918118
    [No Abstract]   [Full Text] [Related]  

  • 50. Metastatic breast cancer: an analysis of prognostic factors in patients treated with aminoglutethimide.
    Repetto L; Pronzato P; Ardizzoni A; Bertelli G; Gulisano M; Amoroso D; Gardin G; Fusco V; Falcone A; Conte PF
    Chemioterapia; 1987 Feb; 6(1):66-72. PubMed ID: 3829138
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pancytopenia induced by aminoglutethimide in the treatment of breast cancer.
    Lawrence B; Santen RJ; Lipton A; Harvey HA; Hamilton R; Mercurio T
    Cancer Treat Rep; 1978 Oct; 62(10):1581-3. PubMed ID: 213192
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hormonal treatment of disseminated male breast cancer.
    Lopez M; Di Lauro L; Lazzaro B; Papaldo P
    Oncology; 1985; 42(6):345-9. PubMed ID: 2933617
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer.
    Ingle JN; Green SJ; Ahmann DL; Long HJ; Edmonson JH; Rubin J; Chang MN; Creagan ET
    J Clin Oncol; 1986 Jun; 4(6):958-64. PubMed ID: 3519885
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Studies in patients with metastatic breast carcinoma treated with aminoglutethimide for medical adrenalectomy.
    Wells SA; Haagensen DE; Misbin R; Lipton A; Smart E; Santen RJ
    Surg Forum; 1976; 27(62):101-2. PubMed ID: 1019817
    [No Abstract]   [Full Text] [Related]  

  • 55. [Treatment of metastasizing breast cancer with aminoglutethimide].
    Kübböck J; Ludwig H; Aiginger P; Linkesch W; Pötzi P
    Acta Med Austriaca; 1982; 9(5-6):221-6. PubMed ID: 7164757
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
    Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I
    Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Low-dose aminoglutethimide therapy without cortisol substitution in postmenopause metastasizing breast cancer].
    Höffken K; Miller AA; Miller B; Becher R; Aulbert E; Hoffmann B; Anders CU; Callies R; Schmidt CG
    Med Klin (Munich); 1986 Oct; 81(20):638-42. PubMed ID: 3785061
    [No Abstract]   [Full Text] [Related]  

  • 58. [Experiences with Rodazol therapy in the treatment of postmenopausal patients with metastatic breast cancer].
    Stier G; Gürtler R; Schmidt UM; Müller U; Tanneberger S
    Zentralbl Gynakol; 1990; 112(17):1101-4. PubMed ID: 2264420
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Medical treatment for advanced breast cancer.
    Carbone PP; Davis TE
    Semin Oncol; 1978 Dec; 5(4):417-27. PubMed ID: 366755
    [No Abstract]   [Full Text] [Related]  

  • 60. [Aminoglutethimide in the treatment of metastasizing breast carcinoma in old age].
    Gorgone S; Lorenzini C; Palmeri R; Belnome N; Calbo L; Dattola P; Melita P
    Chir Ital; 1987 Apr; 39(2):166-75. PubMed ID: 3652316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.